A61K 38/09
Luteinising hormone-releasing hormone [lhrh] , i.e. gonadotropin-releasing hormone [gnrh]
Official title: Luteinising hormone-releasing hormone [LHRH] {, i.e. Gonadotropin-releasing hormone [GnRH]}; Related peptides
A61K38/09 (Luteinising hormone-releasing hormone [lhrh] , i.e. gonadotropin-releasing hormone [gnrh]) appears on 510 US grants and 787 published applications in this corpus.
Search patents in A61K- Granted patents
- 510
- Published applications
- 787
- Assignees
- 375
- Inventors
- 1,153
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 1 | 0 |
| 1980 | 1 | 0 |
| 1981 | 3 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 5 | 0 |
| 1988 | 4 | 0 |
| 1989 | 2 | 0 |
| 1990 | 3 | 0 |
| 1991 | 5 | 0 |
| 1992 | 7 | 0 |
| 1993 | 5 | 0 |
| 1994 | 7 | 0 |
| 1995 | 5 | 0 |
| 1996 | 14 | 0 |
| 1997 | 12 | 0 |
| 1998 | 14 | 0 |
| 1999 | 15 | 0 |
| 2000 | 22 | 0 |
| 2001 | 20 | 6 |
| 2002 | 10 | 31 |
| 2003 | 11 | 23 |
| 2004 | 12 | 34 |
| 2005 | 9 | 26 |
| 2006 | 7 | 37 |
| 2007 | 10 | 48 |
| 2008 | 4 | 35 |
| 2009 | 5 | 36 |
| 2010 | 15 | 37 |
| 2011 | 10 | 26 |
| 2012 | 13 | 22 |
| 2013 | 15 | 27 |
| 2014 | 15 | 35 |
| 2015 | 16 | 35 |
| 2016 | 25 | 36 |
| 2017 | 37 | 43 |
| 2018 | 20 | 32 |
| 2019 | 20 | 32 |
| 2020 | 21 | 24 |
| 2021 | 17 | 38 |
| 2022 | 16 | 41 |
| 2023 | 16 | 20 |
| 2024 | 13 | 24 |
| 2025 | 17 | 19 |
| 2026 | 8 | 20 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method of treating a child with central precocious puberty using an extended release composition6 Oct 2026US 12,751,990 B2Tolmar International Limited
- Progesterone formulation to trigger ovulation and provide luteal phase support15 Sep 2026US 12,734,179 B2Augusta University Research Institute, Inc.
- Methods of manufacturing injectable sustained release formulations14 Jul 2026US 12,678,476 B2Foresee Pharmaceuticals Co., Ltd.
- Immunotherapeutic for prostate cancer treatment9 Jun 2026US 12,648,985 B2Hexamer Therapeutics, Inc.
- Methods of treating prostate cancer with GnRH antagonist27 Jan 2026US 12,533,387 B2Ferring B. V.
- Testosterone and difluoromethylornithine combination therapy for prostate cancer24 Sep 2026US 2026/0284076 A1The Johns Hopkins University
- Injectable gel composition17 Sep 2026US 2026/0272823 A1Maman Biomedical Inc.
- Degarelix organic solvent formulations13 Aug 2026US 2026/0232573 A1
- Stable parenteral dosage form of cetrorelix acetate6 Aug 2026US 2026/0224656 A1Sun Pharmaceutical Industries Limited
- Indole compound decomposing ikzf2, and use thereof30 Jul 2026US 2026/0216164 A1Korea Research Institute of Bioscience and Biotechnology
Most cited
By later US patents
- Microencapsulation of water soluble active polypeptides483US 4,675,189 ASyntex (U.S.A.) Inc. · 1987
- Sustained delivery of leuprolide using an implantable system394US 5,728,396 AAlza Corporation · 1998
- Drug delivery system and method of making the same385US 4,897,268 ASouthern Research Institute · 1990
- Prolonged release microcapsule and its production372US 4,652,441 ATakeda Chemical Industries, Ltd. · 1987
- Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix365US 6,309,669 B1The United States of America as represented by the Secretary of the Army · 2001